We offer a prevention-focused PRS panel (ARC-PREVENT) for proactive risk profiling, and six indication-anchored tests (ARC-CHD, ARC-CHOL, ARC-TRIG, ARC-VTE, ARC-CKD, ARC-T2D) that integrate polygenic risk with family history and/or rare-variants.
A prevention-focused PRS panel (ARC-PREVENT) for proactive risk profiling includes PRS for coronary heart disease (CHD), atrial fibrillation, venous thromboembolism (VTE), abdominal aortic aneurysm (AAA), chronic kidney disease (CKD) and type 2 diabetes (T2D). The six indication-anchored ARC tests (ARC-CHD, ARC-CHOL, ARC-TRIG, ARC-VTE, ARC-CKD, ARC-T2D) integrate polygenic risk with family history and/or rare-variants. These are meant to facilitate management of the following conditions: coronary heart disease (CHD), severe hypercholesterolemia (LDL-C >190 mg/dL), severe hypertriglyceridemia (triglyceride levels >500 mg/dL), venous thromboembolism (VTE), chronic kidney disease (CKD) and type 2 diabetes (T2D).
Scores are computed with the PRSMix ensemble method and calibrated on genotype-derived principal components projected to a multi-ancestry reference exceeding 100,000 individuals, supporting wide applicability across ancestrally varied populations.
Every report is signed out by the clinical laboratory director. Analytic and clinical validity are documented against defined action thresholds — not presented as certainty where the evidence is provisional.
01
The Care Team places the order in the ARC-omix portal and provides clinical data through standardized questions at the time of ordering.
02
Blended Genome-Exome (BGE) sequencing on one specimen through our partner lab — supporting both rare-variant identification and genome-wide polygenic scoring.
03
Polygenic burden, monogenic status, and family history are combined on a version-locked pipeline into an absolute-risk estimate anchored to the relevant clinical comparator.
04
A thorough report with clinical decision support delivered to the ordering provider.
A saliva or blood sample undergoes Blended Genome-Exome (BGE) sequencing, integrated genomic risk is computed using ARC-omix proprietary algorithms, and returned to the ordering clinician with clinical decision support.
Our first two tests are available to order now.